Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
31,500
Employees31,500
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
31,500
Employees31,500

AMGN Key Statistics

Market cap
203.57B
Market cap203.57B
Price-Earnings ratio
26.54
Price-Earnings ratio26.54
Dividend yield
2.56%
Dividend yield2.56%
Average volume
2.62M
Average volume2.62M
High today
$379.87
High today$379.87
Low today
$373.00
Low today$373.00
Open price
$374.99
Open price$374.99
Volume
2.30M
Volume2.30M
52 Week high
$391.29
52 Week high$391.29
52 Week low
$261.43
52 Week low$261.43

Stock Snapshot

Amgen(AMGN) stock is priced at $373.25, giving the company a market capitalization of 203.57B. It carries a P/E multiple of 26.54 and pays a dividend yield of 2.6%.

As of 2026-03-12, Amgen(AMGN) stock has fluctuated between $373.00 and $379.87. The current price stands at $373.25, placing the stock +0.1% above today's low and -1.7% off the high.

Amgen(AMGN) shares are trading with a volume of 2.3M, against a daily average of 2.62M.

During the past year, Amgen(AMGN) stock moved between $261.43 at its lowest and $391.29 at its peak.

During the past year, Amgen(AMGN) stock moved between $261.43 at its lowest and $391.29 at its peak.

AMGN News

Barron's 2h
Starbucks, Amgen, and CVS Help This Income Fund Shine

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. Fo...

Starbucks, Amgen, and CVS Help This Income Fund Shine
24/7 Wall St. 2d
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained

Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street’s Latest Biopharma Calls Explained Quick Read Jefferies initiated on Gilead (GILD) w...

Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained
TipRanks 2d
Amgen initiated with a Hold at Jefferies

Jefferies initiated coverage of Amgen (AMGN) with a Hold rating and $350 price target With the stock having run up about 35% over the past six months, driven by...

Analyst ratings

53%

of 38 ratings
Buy
39.5%
Hold
52.6%
Sell
7.9%

More AMGN News

Nasdaq 4d
Better Weight Loss Stock: Novo Nordisk Vs. Amgen

Key Points Novo Nordisk is a top player in the weight loss market and has several more products on the way. Amgen's most advanced candidate in this space coul...

Better Weight Loss Stock: Novo Nordisk Vs. Amgen
Simply Wall St 4d
Assessing Amgen Valuation After Rocatinlimab Trial Halt And Pipeline Setback

Amgen (AMGN) has come under fresh scrutiny after it and Kyowa Kirin halted all clinical trials for rocatinlimab, following a safety review that cited potential...

Assessing Amgen Valuation After Rocatinlimab Trial Halt And Pipeline Setback
Simply Wall St 6d
Will Amgen's Steady Dividend and Earnings Beats Redefine Its Capital Allocation Narrative?

In early March 2026, Amgen’s board declared a US$2.52 per-share second-quarter dividend, payable on June 5, 2026, to shareholders of record as of May 15, while...

Will Amgen's Steady Dividend and Earnings Beats Redefine Its Capital Allocation Narrative?
Simply Wall St 7d
Rocatinlimab Halt Puts Spotlight On Amgen Pipeline Mix And Valuation Gap

Amgen (NasdaqGS:AMGN) and Kyowa Kirin have decided to discontinue clinical development of rocatinlimab. The decision follows emerging safety concerns identifie...

Rocatinlimab Halt Puts Spotlight On Amgen Pipeline Mix And Valuation Gap

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.